SkyLake Equity Partners

Company

Related News

MEDIPOST Treats First U.S. Participant in Phase III Stem Cell Therapy Trial for Knee Osteoarthritis

Jul 08, 2026

MEDIPOST treated the first U.S. participant in a Phase III trial of its umbilical cord blood-derived MSC therapy for knee osteoarthritis. The FDA agreed the single pivotal study, supported by prior trials in South Korea and Japan, can support a planned BLA filing.

MEDIPOST Files IND Amendment for Phase III Knee Osteoarthritis Stem Cell Trial

Feb 14, 2026

MEDIPOST has submitted an investigational new drug amendment to the FDA to initiate a Phase III trial of its umbilical cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis, with patient enrollment expected in the first half of 2026.